Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity

Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00162799

Enrollment

Registered

2005-09-13

Start date

2002-07-31

Completion date

2004-12-31

Last updated

2006-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance

Keywords

insulin resistance and inflamation, insulin sensitibity, obesity-induced insuline resistence, obesity-diabetes link, salicylate, insulin resistance in obesity health adults

Brief summary

To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.

Detailed description

Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled. Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days Washout period: 30 days

Interventions

DRUGTriflusal (DCI)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

35 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Ages 35 to 60 years old

Design outcomes

Primary

Measure	Time frame
Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).	—

Secondary

Measure	Time frame
Reduction antropometric measures associated with insulin resistance and arterial hypertension.	—

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026